Is There a Biosimilar for Humira? Yes, Here Are 10 Humira Biosimilars to Choose From

If you’re prescribed Humira (adalimumab), you may have wondered when a generic version was going to be available. But Humira isn’t like most medications found on pharmacy shelves. It’s a biologic, meaning it comes from living sources, like animal or plant cells.

Biologics don’t have generics. Instead, they have biosimilars. These are medications that are highly similar to the original (reference) medication, often available at a lower cost.

More than 20 years after the original medication first launched, 10 Humira biosimilars have been approved and are available on the market. Read on to explore these potential Humira alternatives.

What is Humira?

Humira is an injectable tumor necrosis factor (TNF) blocker. This means it works by blocking the protein TNF, which causes inflammation in the body. Humira is FDA approved to treat several autoimmune conditions in adults and children, including those listed in the chart below.

Humira is packaged in three different ways: a prefilled pen, a prefilled syringe, and a vial. It also comes in several different doses, ranging from 10 mg to 80 mg. Humira is usually administered once a week or once every other week.

Humira vs. Humira biosimilars

There are a few differences between Humira and the approved Humira biosimilars. First, most of the biosimilars are only approved for HS and uveitis in adults, not children. They also have varying concentrations and doses.

Disclosure

Humira

Avg retail price

$3,899.89(Save 92.90%)

GoodRx discount

$277.00

See all discounts

How it works

Use GoodRx to find medications, pharmacies, and discounts.

GoodRx discounts can help you pay less for your prescription.

Bring your free coupon or savings card to the pharmacy.

When Humira products were first introduced, they used a formulation that had a relatively low concentration of the active ingredient and contained citrate, an ingredient that can make injections more painful. These products are still available, and most of the biosimilars are based on this original, low-concentration formula. But many of them don’t contain citrate.

Newer Humira products are citrate-free and come in higher concentrations, so they deliver the same amount of medication in a smaller amount of liquid. This may make injections easier and faster. A few biosimilars have high-concentration forms approved or under FDA review.

Some biosimilars are considered interchangeable with Humira. This means they’ve gone through additional studies to determine that it’s possible to switch back and forth between the biosimilar and the original product without issues. In some states, pharmacists can more easily substitute an interchangeable Humira biosimilar with Humira without contacting your prescriber.

The chart below summarizes all of the approved Humira biosimilars. In the following sections, we’ll review each of these biosimilars in detail.

1. Amjevita

Amjevita became the first FDA-approved Humira biosimilar in September 2016. And, on January 31, 2023, it became the first Humira biosimilar to launch in the U.S. Amjevita is considered interchangeable with Humira.

Amjevita is currently available in prefilled autoinjector pens (40 mg and 80 mg) and prefilled syringes (10 mg, 20 mg, 40 mg, and 80 mg). Amjevita products come in both high- and low-concentration, citrate-free forms.

EXPERT PICKS: WHAT TO READ NEXT

• Making the switch: Thinking about switching to a Humira biosimilar? Here are some questions to ask your pharmacist to see if a biosimilar is right for you.

• Knowing the difference: Experts discuss the key differences between biosimilars and generics, and when you might be prescribed one instead of the other.

• How to save: Biosimilars can help you save money at the pharmacy. Learn more about ways to save on biosimilars with copay cards, rebates, and more.

2. Cyltezo

Cyltezo became the second FDA-approved Humira biosimilar in August 2017. In October 2021, it also became the first biosimilar to be designated as interchangeable with Humira. And it launched on July 1, 2023.

Cyltezo is currently available as a prefilled pen (40 mg) and syringes (10 mg, 20 mg, and 40 mg). The 40 mg doses are available in both low-concentration and high-concentration forms. The rest of the doses are low concentration only. All forms are citrate free.

Cyltezo is also available as an unbranded product called adalimumab-adbm. The unbranded product is the same as Cyltezo, but without the Cyltezo brand name. It comes in the same doses and dosage forms as Cyltezo and is interchangeable with Humira. Anyone with a valid prescription, regardless of insurance status, can use GoodRx to purchase two adalimumab-adbm pens at an exclusive cash price of $550.

3. Hyrimoz

In October 2018, Hyrimoz became the third FDA-approved Humira biosimilar. It’s available in the following doses and forms, which are considered interchangeable with Humira:

• Injection pens: 40 mg (low concentration); 40 mg and 80 mg (high concentration)

• Prefilled syringes: 10 mg, 20 mg, and 40 mg (low concentration); 10 mg, 20 mg, 40 mg, and 80 mg (high concentration)

The low-concentration forms contain citric acid, which is closely related to citrate. Citric acid can also make injections more painful. The high-concentration forms are citrate-free.

The high-concentration, citrate-free versions of Hyrimoz launched in the U.S. on July 1, 2023.

4. Hadlima

Hadlima became the fourth FDA-approved Humira biosimilar in July 2019. Hadlima officially launched in the U.S. on July 1, 2023. Hadlima is considered to be interchangeable with Humira.

Hadlima is available in both an autoinjector and a syringe in a 40 mg dose. Both low- and high-concentration forms are available. The high-concentration forms are citrate-free. A low-concentration vial is available for use in healthcare facilities.

5. Abrilada

Abrilada became the fifth FDA-approved Humira biosimilar in November 2019. It was also the second interchangeable Humira biosimilar to be approved. Abrilada officially launched in late November 2023.

Abrilada is available in a prefilled pen (40 mg) and syringes (10 mg, 20 mg, and 40 mg). All Abrilada products are low concentration and citrate-free. A vial is available for use in healthcare facilities.

6. Hulio

Hulio became the sixth FDA-approved Humira biosimilar in July 2020. And it launched in the U.S. in early July 2023. Hulio is considered interchangeable with Humira.

Hulio is available in a prefilled pen (40 mg) and syringes (20 mg and 40 mg). All forms are low concentration and citrate-free. Hulio is also available in the same doses and forms as an unbranded product called adalimumab-fkjp.

7. Yusimry

Yusimry became the seventh FDA-approved Humira biosimilar in December 2021. And it also launched in the U.S. in early July 2023.

Yusimry is only available in a low-concentration and citrate-free 40 mg prefilled pen and syringe.

8. Idacio

Idacio became the eighth FDA-approved Humira biosimilar in December 2022. Idacio officially launched in the U.S. in early July 2023.

Idacio is available in a 40 mg dose prefilled pen, vial, and syringe. All forms are low concentration and citrate-free.

9. Yuflyma

Yuflyma became the ninth FDA-approved Humira biosimilar in late May 2023, launching in early July 2023. Yuflyma is considered interchangeable with Humira. It’s currently the only Humira biosimilar approved for HS and uveitis for both children and adults.

Yuflyma is available in prefilled syringes (20 mg, 40 mg, and 80 mg) and autoinjectors (40 mg and 80 mg). All products are high concentration and citrate-free. An unbranded version called adalimumab-aaty is also available.

10. Simlandi

Simlandi became the 10th FDA-approved Humira biosimilar in February 2024. It was the first high-concentration and citrate-free interchangeable Humira biosimilar. Simlandi comes as an autoinjector (40 mg, 80 mg) and prefiled syringe (20 mg, 40 mg, 80 mg).

How to choose the best Humira biosimilar

So, should you switch to a Humira biosimilar? It depends. There are a few things to consider when discussing your options with your prescriber:

• Why you’re using it: If your child is using Humira for HS or uveitis, Yuflyma is the only option for children. The other biosimilars are not approved for children to use for these conditions.

• Your dosage: If you’re using the 40 mg dose of Humira, you’ll have many options to choose from. Your options may be more limited if you need a different dose.

• The ingredients: If you’re currently using a citrate-free Humira product (or you’re looking to switch to one), you’ll have several options. Most Humira biosimilars don’t contain citrate.

• The concentration: If you’re currently using a high-concentration Humira product, you have a few biosimilar options, depending on the dosage you need.

• Your insurance coverage: Your insurance plan may offer better coverage for Humira than for biosimilars. Or it may prefer certain Humira biosimilars over others. If you’re thinking about switching your medication and have health insurance, it’s a good idea to check with your plan about coverage first.

• Ways to save: Manufacturer copay cards may be available for some of the biosimilars. This could help make your prescription more affordable. If you’re uninsured or underinsured, you may be eligible for a patient assistance program.

Frequently asked questions

Why trust our experts?

Written by:

Alyssa Billingsley, PharmD

Alyssa Billingsley, PharmD, is the director of pharmacy content for GoodRx. She has over a decade of experience as a pharmacist and has worked in clinical, academic, and administrative roles.

Reviewed by:

Joshua Murdock, PharmD, BCBBS

Joshua Murdock, PharmD, BCBBS, is a licensed pharmacist in Arizona, Colorado, and Rhode Island. He has worked in the pharmacy industry for more than 10 years and currently serves as a pharmacy editor for GoodRx.

Our editorial standards

Meet our experts